Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OpGen, Inc.
  6. News
  7. Summary
    OPGN   US68373L3078

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OpGen : Corporate Presentation (PDF)

10/04/2021 | 08:48am EST

OpGen

Corporate Overview

October 4, 2021

OpGen, Inc.

Forward Looking Statements Disclaimer

This presentation contains forward-looking statements that are subject to many risks and uncertainties. These statements, among other things, relate to our business strategy, goals and expectations concerning our products, future operations, prospects, plans and objectives of management. The words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will" and similar terms and phrases are used to identify forward-looking statements in this presentation. These statements and other statements regarding our future plans constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1955. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond OpGen's control, and that may cause results to differ materially from expectations.

Factors that could cause results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and service offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, the realization of expected synergies from our business combination transaction with Curetis GmbH, the successful integration of our company with the operations and business of Curetis GmbH and its subsidiaries and the implementation of the combined company's strategic and business goals and objectives, the impact of COVID-19 on our operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the ability to comply with the complexities of operating a global business, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen, Inc.

2

OpGen Overview

Striving to innovate molecular microbiology

Fast

Comprehensive

Smart

Easy

Rapid Pathogen

Broad Pathogen &

AI-Powered AMR

Sample-To-Answer

Detection For Life

Antimicrobial

Prediction &

Platforms

Threatening Infections

Resistance (AMR)

Bioinformatics

Marker Coverage

OpGen, Inc.

3

OpGen's combined portfolio

Synergistic products and capabilities

Unyvero Platform &

Acuitas Panel &

Global Commercial

Ares Genetics NGS &

Syndromic Tests

Lighthouse

Presence

Bioninformatics

FDA-cleared LRT & LRT BAL for

FDA-cleared Acuitas AMR Gene

Direct sales and marketing in the

lower respiratory tract infections

Panel for Isolates

U.S.

5 CE-IVD tests

Enhances targeted antibiotic

EMEA, APAC, Latin America and

Unyvero A30 RQ platform in

decision making

China distribution with partners

Lighthouse knowledge base

advanced stages of development

deployed for public health use

OpGen, Inc.

AI-powered AMR prediction combining ARESdb with NGS

Strategic partnerships and collaborations with globally leading IVD & pharma companies

4

OpGen's strategic positioning and benefits

Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms

Premier AI-powered bioinformatics solutions for multi-drug resistance diagnostics

Global commercial channel capabilities & partners

Financial leverage, operational synergies, and positive growth-driven business outlook

OpGen, Inc.

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

OpGen Inc. published this content on 04 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 October 2021 12:44:33 UTC.


ę Publicnow 2021
All news about OPGEN, INC.
11/12OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update - Form ..
PU
11/11OpGen, Inc. Provides Revenue Guidance for the Year 2021
CI
11/11Earnings Flash (OPGN) OPGEN Reports Q3 Revenue $1.2M, vs. Street Est of $1.2M
MT
11/11OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update
GL
11/11OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem..
CI
11/04OpGen Corporate Presentation (PDF)
PU
11/04OpGen Appoints Albert Weber as Chief Financial Officer - Form 8-K
PU
11/04OPGEN INC : Change in Directors or Principal Officers, Other Events, Financial Statements ..
AQ
11/04Executive Video Interview with Oliver Schacht, Ph.D., OpGen CEO - Form 8-K
PU
11/04OPGEN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on OPGEN, INC.
More recommendations
Financials (USD)
Sales 2021 3,80 M - -
Net income 2021 -35,9 M - -
Net cash 2021 8,88 M - -
P/E ratio 2021 -1,59x
Yield 2021 -
Capitalization 61,5 M 61,5 M -
EV / Sales 2021 13,9x
EV / Sales 2022 9,16x
Nbr of Employees 102
Free-Float 99,7%
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,58 $
Average target price 4,18 $
Spread / Average Target 164%
EPS Revisions
Managers and Directors
Oliver Schacht President, Chief Executive Officer & Director
William E. Rhodes Non-Executive Chairman
Vadim Sapiro Chief Information Officer
Faranak Atrzadeh Chief Marketing & Scientific Affairs Officer
Johannes Bacher Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
OPGEN, INC.-22.55%62
MODERNA, INC.161.69%110 846
LONZA GROUP AG25.95%56 890
IQVIA HOLDINGS INC.48.11%50 694
SEAGEN INC.-1.11%31 671
CELLTRION, INC.-40.39%23 975